Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study
Authors
Pignata, S.Oza, A. M.
Hall, G.
Pardo, B.
Madry, R.
Cibula, D.
Klat, J.
Montes, A.
Glasspool, R.
Colombo, N.
Pete, I.
Herrero, A.
Romeo, M.
Ilieva, R. N.
Timcheva, C.
Di Maio, M.
Barnicle, A.
Taylor, R.
Bashir, Z.
Clamp, Andrew R
Affiliation
Istituto Nazionale Tumori ‘Fondazione G Pascale’, IRCCS, Napoli, ItalyIssue Date
2022
Metadata
Show full item recordCitation
Pignata S, Oza AM, Hall G, Pardo B, Madry R, Cibula D, et al. Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301572.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.5519Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.5519Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.5519